173 related articles for article (PubMed ID: 8384811)
1. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.
Lalande V; Truffot-Pernot C; Paccaly-Moulin A; Grosset J; Ji B
Antimicrob Agents Chemother; 1993 Mar; 37(3):407-13. PubMed ID: 8384811
[TBL] [Abstract][Full Text] [Related]
2. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
Grosset J; Truffot-Pernot C; Lacroix C; Ji B
Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
JI B; Lounis N; Truffot-Pernot C; Grosset J
Antimicrob Agents Chemother; 1995 Jun; 39(6):1341-4. PubMed ID: 7574527
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.
Ji B; Perani EG; Petinon C; Grosset JH
Int J Lepr Other Mycobact Dis; 1992 Dec; 60(4):556-61. PubMed ID: 1338596
[TBL] [Abstract][Full Text] [Related]
5. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?
Lounis N; Ji B; Truffot-Pernot C; Grosset J
Antimicrob Agents Chemother; 1997 Mar; 41(3):607-10. PubMed ID: 9056001
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.
Ji B; Lounis N; Maslo C; Truffot-Pernot C; Bonnafous P; Grosset J
Antimicrob Agents Chemother; 1998 Aug; 42(8):2066-9. PubMed ID: 9687408
[TBL] [Abstract][Full Text] [Related]
7. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
8. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
[TBL] [Abstract][Full Text] [Related]
9. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
Grosset J; Truffot C; Fermanian J; Lecoeur H
Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
[TBL] [Abstract][Full Text] [Related]
10. [Antimycobacterial activities of a new quinolone, sparfloxacin].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
[TBL] [Abstract][Full Text] [Related]
12. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
[TBL] [Abstract][Full Text] [Related]
13. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
[TBL] [Abstract][Full Text] [Related]
14. Activity of levofloxacin in a murine model of tuberculosis.
Klemens SP; Sharpe CA; Rogge MC; Cynamon MH
Antimicrob Agents Chemother; 1994 Jul; 38(7):1476-9. PubMed ID: 7979275
[TBL] [Abstract][Full Text] [Related]
15. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
Byrne ST; Denkin SM; Gu P; Nuermberger E; Zhang Y
J Med Microbiol; 2007 Aug; 56(Pt 8):1047-1051. PubMed ID: 17644711
[TBL] [Abstract][Full Text] [Related]
16. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
[TBL] [Abstract][Full Text] [Related]
17. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
18. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].
Kawahara S; Kamisaka K; Tada A; Nakada H; Mishima Y; Yoshimoto S; Matsuyama T; Kibata M; Nagare J
Kekkaku; 1991 Jun; 66(6):429-31. PubMed ID: 1942726
[TBL] [Abstract][Full Text] [Related]
19. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.
Lecoeur HF; Truffot-Pernot C; Grosset JH
Am Rev Respir Dis; 1989 Nov; 140(5):1189-93. PubMed ID: 2817579
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Saito H; Tomioka H; Sato K; Kawahara S; Hidaka T; Dekio S
Tuber Lung Dis; 1995 Feb; 76(1):51-8. PubMed ID: 7718848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
